Insurance coverage for GLP-1 weight loss medications (Wegovy, Zepbound, and compounded semaglutide or tirzepatide) exists in 2026, but what your plan actually pays depends almost entirely on which plan type you carry. Commercial insurance often pays with prior authorization. Medicare covers Wegovy for one narrow group. Medicaid rarely helps. Compounded GLP-1 is almost never reimbursed by any insurer. But it can be the smarter financial choice even when insurance coverage is technically available.
By Alexandru Vieru | Independently researched | Published August 2026. Insurance coverage data verified: August 2026.
Quick answer: GLP-1 insurance coverage is available from most large commercial carriers (UnitedHealthcare, Aetna, Cigna, and Blue Cross Blue Shield) for patients with BMI ≥30 or BMI ≥27 plus a qualifying comorbidity, subject to prior authorization. Medicare Part D covers Wegovy specifically for patients with established cardiovascular disease (CVD); the standard benefit does not cover Zepbound, though the temporary Medicare GLP-1 Bridge covers both drugs for eligible enrollees. Medicaid insurance coverage for GLP-1 is a state-by-state patchwork and mostly unavailable in mid-2026. If your plan denies you or your deductible makes insurance coverage impractical, compounded semaglutide from licensed telehealth clinics runs $99–$199/month, against $349/month for the brand-name Wegovy pen self-pay through NovoCare (checked 12 October 2026).
| Plan type | Wegovy covered? | Zepbound covered? | Prior auth needed? |
|---|---|---|---|
| Commercial (employer/marketplace) | Often yes | Often yes | Yes. BMI + diagnosis + PA |
| Medicare Part D | CVD patients; Medicare GLP-1 Bridge | Standard benefit no; KwikPen via Medicare GLP-1 Bridge | Yes. CVD documentation or Bridge eligibility |
| Medicare Advantage | Varies by plan | Varies by plan | Yes |
| Medicaid | Rarely | Rarely | Varies by state |
| Uninsured / cash pay | NovoCare self-pay: pen $349/mo, pill $149 to $299/mo | LillyDirect self-pay $299 to $449/mo | No PA |
| Compounded sema/tirz | Not covered | Not covered | No. Cash pay only |
For the full cost breakdown, what all-in compounded prices look like versus brand retail, see our GLP-1 cost guide for 2026.
GLP-1 Insurance Coverage in 2026: The Three Plan Types
The single biggest factor in your GLP-1 insurance coverage is not your BMI or your health history. It is which plan type you carry.
Commercial insurance (employer-sponsored, marketplace, or individual plans) gives you the best shot at insurance coverage for weight loss drugs. Major carriers have been expanding coverage for anti-obesity medications since 2023, driven by the growing clinical evidence base from the STEP and SURMOUNT trial programs. Coverage still requires prior authorization in virtually every case, and a significant number of large employers dropped GLP-1 insurance coverage between 2023 and 2025 due to the steep annual cost per member. But the majority of large-group plans still include it.
Medicare Part D has a statutory exclusion for weight-loss drugs dating to 2003. But a 2024 CMS update carved out a narrow exception for Wegovy when it is prescribed for cardiovascular risk reduction, not obesity alone. This exception does not apply to Zepbound. Full details below.
Medicaid is the hardest path. The federal government proposed a rule that would have required states to cover GLP-1 medications for obesity, but that rule was not finalized in time. As of mid-2026, GLP-1 insurance coverage through Medicaid is purely state-by-state. And most states have not added it.
Commercial Insurance Coverage for GLP-1 Medications
The four largest U.S. commercial carriers all offer some form of GLP-1 insurance coverage on their commercial plans in 2026. The specifics vary significantly by plan, and your employer ultimately controls whether the benefit is included if you have employer-sponsored coverage.
| Insurer | Wegovy | Zepbound | Key prior auth conditions |
|---|---|---|---|
| UnitedHealthcare | Yes (commercial) | Yes (commercial) | BMI ≥30 or ≥27 + 1 comorbidity; 3-month diet documentation |
| Aetna | Yes | Yes | BMI ≥30 or ≥27 + obesity-related diagnosis; PA required |
| Cigna | Varies by employer plan | Varies | PA required; formulary tier varies |
| BCBS (Federal/large group) | Yes (many plans) | Yes (many plans) | PA; step therapy may apply |
| Humana | Limited on commercial | Limited | PA; prior weight-loss program required |
The employer wild card. Even if your insurer lists Wegovy or Zepbound on its formulary, your employer controls the actual benefit design for employer-sponsored plans. Hundreds of large employers, including major corporations with self-insured plans, dropped GLP-1 insurance coverage in 2023–2024 because a single covered employee's annual drug cost can exceed $14,000. Before assuming your plan has coverage, verify directly with your HR or benefits administrator.
Marketplace plans. Health plans sold on healthcare.gov often include Wegovy and Zepbound at Tier 3–4 pricing. After your deductible is met, your cost share typically runs $50–$200/month per prescription depending on your plan's design. The problem: if you have a high-deductible plan and you start GLP-1 therapy early in the year, you may pay the full price until the deductible is met; for comparison, the Wegovy pen is $349/month self-pay through NovoCare (checked 12 October 2026). In that window, compounded semaglutide is the far cheaper path.
For a side-by-side look at what all cash-pay options cost, see our cheapest GLP-1 clinic guide.
Prior Authorization Checklist: What Your Insurer Requires
Prior authorization (PA) is required for GLP-1 insurance coverage at every major carrier in 2026. Your prescribing clinician submits the PA on your behalf. But knowing what documentation is needed helps you move faster and avoid a denial.
Medical eligibility your prescriber must document:
- BMI ≥30.0 (obesity class I, II, or III), or
- BMI ≥27.0 plus at least one weight-related comorbidity: type 2 diabetes, hypertension, obstructive sleep apnea, or dyslipidemia
ICD-10 diagnosis codes typically used:
- E66.01. Morbid obesity due to excess calories
- E66.09. Other obesity
- E11.x. Type 2 diabetes (if applicable)
- I10. Essential hypertension (if applicable)
- G47.33. Obstructive sleep apnea (if applicable)
Treatment history most insurers require:
- Documentation of a structured, medically supervised weight-management attempt. Most carriers ask for 3–6 months of prior efforts (diet counseling, behavioral program, or pharmacotherapy).
- Step therapy: Some insurers require a trial of a lower-cost agent (phentermine, bupropion/naltrexone) before approving a GLP-1. Check your plan's step-therapy policy upfront.
PA submission process:
- Your prescriber submits the PA electronically or by fax.
- Your insurer reviews within 72 hours (urgent) or up to 14 days (standard).
- If denied: request a peer-to-peer review, where your doctor speaks directly to the insurer's medical director. Approval rates at peer-to-peer are meaningfully higher than at initial review.
- Still denied: file a formal appeal citing the SELECT trial (Wegovy: fewer major cardiovascular events than placebo in adults with preexisting cardiovascular disease and overweight or obesity) or SURMOUNT-1 data (Zepbound: 20.9% mean weight reduction at 72 weeks on the 15 mg dose).
Wellorithm, which offers brand-name Wegovy, Ozempic, Mounjaro, and Zepbound alongside compounded options, handles the prior authorization process internally for patients pursuing brand-name medications. If your PA is denied, they pivot to compounded options from $247/month ($147 first month). Visit Wellorithm →
Medicare and GLP-1: The Wegovy CVD Exception
The weight-loss exclusion. Medicare Part D plans are legally prohibited from paying for drugs "used for anorexia, weight loss, or weight gain" under the Social Security Act (§1860D-2(e)(2)(A)). This statutory exclusion has applied to anti-obesity medications since the Medicare Modernization Act of 2003.
The 2024 exception for Wegovy. In March 2024, FDA approved an additional indication for semaglutide (Wegovy): reducing the risk of serious cardiovascular events (heart attack, stroke, cardiovascular death) in adults with obesity or overweight who have established cardiovascular disease. The SELECT trial underpinning this approval showed a 20% relative reduction in major adverse cardiovascular events (MACE) versus placebo over a mean follow-up of 39.8 months. SELECT trial results (NEJM, 2023).
Because this new indication is cardiovascular, not obesity, CMS guidance issued in early 2024 clarified that Part D plans may cover Wegovy for patients meeting both criteria:
- Established cardiovascular disease (prior heart attack, stroke, peripheral arterial disease, or coronary artery disease with documented stenosis), and
- BMI ≥27 kg/m² (overweight or obese)
Important caveats:
- Part D plans are permitted but not required to add Wegovy for the CVD indication. Check your specific plan's formulary.
- Patients using Wegovy for weight loss alone, without a CVD history, remain excluded.
- Zepbound (tirzepatide): No cardiovascular indication approved as of August 2026. Medicare Part D exclusion applies in full.
- Compounded semaglutide or tirzepatide: Not FDA-approved drugs. Never covered by any federal payer.
Medicare Advantage (Part C). Unlike standalone Part D plans, Medicare Advantage plans have more design flexibility. Some MA plans from large national carriers have added GLP-1 medications as supplemental benefits. Check your plan's Evidence of Coverage document for specifics.
For the Medicare Bridge Program ($50/month Wegovy option for qualifying beneficiaries) and how brand pricing compares to compounded, see our GLP-1 cost guide.
For Zepbound-specific insurance coverage details, including which commercial insurers cover it and how Lilly Direct pricing works, see our Zepbound insurance coverage guide.
Medicaid and GLP-1 Insurance Coverage
The short answer: Most Medicaid programs do not cover GLP-1 medications for obesity in 2026.
CMS proposed a federal rule that would have required state Medicaid programs to cover anti-obesity medications, including GLP-1 drugs. That rule was not finalized before mid-2026, leaving states with full discretion. And the majority have not voluntarily added insurance coverage for GLP-1 weight loss drugs because the per-patient annual cost is substantial.
Where Medicaid GLP-1 coverage exists in 2026:
- States that cover Wegovy or Ozempic for type 2 diabetes (the diabetes indication has no weight-loss exclusion). Patients with T2D and obesity can sometimes access semaglutide through the diabetes pathway.
- A small number of states, including California and some northeastern states, have added limited anti-obesity medication insurance coverage through their state Medicaid programs.
- Some Medicaid Managed Care Organizations (MCOs) have broader formularies than straight fee-for-service Medicaid. Check with your MCO directly.
If Medicaid does not cover it: Compounded semaglutide is the most affordable cash-pay alternative. Gala Health starts at $129/month for compounded semaglutide on a $1,677 prepaid year, in all 50 states; Yucca Health offers the same at $125/month on a 6-month plan. Neither is Medicaid-covered, but both are a fraction of brand retail.
GLP-1 Without Insurance: What Clinics Charge Cash
Without insurance, the realistic route is a telehealth clinic that prescribes compounded semaglutide or tirzepatide for a cash price. These are the ten lowest starting prices among the clinics we rank, each read on the clinic's own page on the date shown. A price marked prepaid is a monthly equivalent of a plan you pay for upfront. The price is the clinic's lowest published rate, usually compounded semaglutide at the starting dose; higher doses and tirzepatide cost more. Each review lists what the price includes.
| Clinic | Lowest verified price | Verified |
|---|---|---|
| Welludr (formerly Wellmedr) | $49/mo | 2026-10-05 |
| SnagRx | $69/mo | 2026-10-05 |
| Embody | $69/mo, 12-month supply (sale) | 2026-10-14 |
| yourEra | $73/mo (homepage, plan length not stated) | 2026-10-15 |
| CoreAge Rx | $79/mo, 12-mo paid in full | 2026-10-14 |
| Oak | $119/mo | 2026-10-11 |
| HealthRX | $99/mo prepaid yr | 2026-10-05 |
| Found | $99/mo | 2026-10-05 |
| Strut Health | $99/mo | 2026-10-05 |
| SkinnyRx | $99/mo | 2026-10-05 |
Compounded GLP-1 is not FDA-approved and is not the same product as brand-name Wegovy or Zepbound. Brand-name self-pay prices start at $149 a month for the lowest Wegovy pill dose and $349 for the Wegovy pen through NovoCare, and $299 to $449 for Zepbound through LillyDirect (checked 12 October 2026). Compounded is usually cheaper at maintenance doses when insurance does not pay.
When Cash-Pay Compounded GLP-1 Beats Insurance Coverage
Even when GLP-1 insurance coverage is available, paying cash for compounded semaglutide can be the better financial decision in four common situations.
Situation 1. High-deductible health plan early in the year. If your HDHP has a $3,000–$6,000 deductible and you start GLP-1 therapy before you've met it, you pay the full price (for comparison, the Wegovy pen is $349/month self-pay through NovoCare). At $79–$199/month through our partner clinics, cash-pay compounded costs less even without any insurance coverage.
Situation 2. Your employer dropped the benefit. Many large employers cut GLP-1 insurance coverage in 2023–2024 due to cost. If your plan no longer includes it, the only realistic option is cash pay. Compounded semaglutide at $99–$199/month is typically 80–90% cheaper than brand-name at retail.
Situation 3. You do not meet PA criteria. If your BMI falls below the threshold with no qualifying comorbidity, you may be denied insurance coverage even if your plan includes GLP-1 on paper. Telehealth compounded clinics evaluate eligibility individually.
Situation 4. You need to start now. Step-therapy requirements mean some insurers want you to try a lower-tier medication first before approving a GLP-1. Cash-pay compounded is the immediate path.
| Scenario | Insurance coverage better? | Compounded cash-pay better? |
|---|---|---|
| Low-deductible plan, deductible already met | ✅ Pay $50–$200 copay/month | — |
| HDHP, early in plan year | — | ✅ $79–$199/month |
| Employer dropped GLP-1 benefit | — | ✅ $99–$199/month |
| Medicare, no CVD history | — | ✅ $99–$199/month |
| Medicaid (most states) | — | ✅ $99–$199/month |
| Need brand-name Wegovy/Zepbound | ✅ Use insurance PA | — |
Is compounded semaglutide legal in 2026? Yes. 503A compounding pharmacies can legally compound semaglutide for individual patients under a valid prescription. Compounded GLP-1 is not FDA-approved and is not equivalent to brand-name Wegovy. For the current legal landscape and what changed after the FDA's June 2026 compounding review, see our compounded GLP-1 legal guide.
How to Check Your GLP-1 Insurance Coverage: 3 Steps
Step 1. Check the formulary. Log in to your insurer's member portal and search for Wegovy (semaglutide injection) or Zepbound (tirzepatide injection) in the drug lookup tool. Note the tier, GLP-1s typically sit at Tier 3 or Tier 4, and whether prior authorization is flagged.
Step 2. Call the benefits line. Even if the drug is on your formulary, call the member services number on your insurance card and ask: "Is Wegovy covered for obesity under my specific plan? What are the PA requirements?" Record the date, representative name, and reference number.
Step 3. Work with your prescriber. Share the PA criteria with your primary care doctor, obesity medicine specialist, or telehealth prescriber. They submit the PA on your behalf. If initially denied, request a peer-to-peer review. The most effective first-line appeal.
If insurance coverage is denied or impractical: Most telehealth GLP-1 clinics handle PA submission for brand-name medications, and pivot to compounded options when insurance coverage is not achievable. See our full clinic comparison to find the right fit for your situation.
Top Picks
If you have insurance coverage and want brand-name Wegovy or Zepbound:
Wellorithm, 7.9/10, carries brand-name Wegovy, Ozempic, Mounjaro, and Zepbound alongside compounded options from $247/month ($147 first month). They navigate the prior authorization process and can pivot to compounded if your insurance coverage is denied.
If you're paying cash for compounded semaglutide or tirzepatide:
- Gala Health (7.0/10, from $129/month on a $1,677 prepaid year) Compounded semaglutide and tirzepatide, plus HRT, in all 50 states.
- Yucca Health (7.5/10, from $125/month on a $750 prepaid 6-month plan) Best Value. LegitScript-certified pharmacy, free 2-day UPS air, both injectable GLP-1s.
- HealthRX (7.8/10, from $99/month) Compounded semaglutide from $99/mo on a 12-month plan. US board-certified physician review within 24 hours; 30-day money-back guarantee.
For a full price comparison across all clinics in our ranking, see our cheapest semaglutide guide.
Related reading:
- How Much Does GLP-1 Weight Loss Cost in 2026?
- Zepbound Insurance Coverage in 2026: Which Plans Pay?
- Is Compounded Semaglutide Still Legal in 2026?
- Compounded vs Brand GLP-1: Cost, Legality & How to Choose
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. GLP-1 medications require a prescription and supervision by a licensed medical provider. Coverage information is subject to change. Verify your specific plan's current coverage rules directly with your insurer and prescriber before making treatment decisions.
Affiliate disclosure: Some links in this guide are affiliate links. We may receive a commission if you visit a partner clinic at no additional cost to you. Our editorial scores are based on independent research and verified evidence. Active partners are listed first at equal displayed scores. Commission rates never influence our rankings or recommendations. See our affiliate disclosure and editorial policy.
Last updated: August 2026. Prices and insurance coverage rules verified as of publication date.
